Flow cytometry improves the diagnostic value of fine needle aspiration cytology in a spleen with neuroendocrine tumor: A case report.
CD45
CD56
fine needle aspiration
flow cytometry
neuroendocrine tumor
spleen
turnaround time
Journal
Diagnostic cytopathology
ISSN: 1097-0339
Titre abrégé: Diagn Cytopathol
Pays: United States
ID NLM: 8506895
Informations de publication
Date de publication:
17 Jun 2023
17 Jun 2023
Historique:
revised:
26
05
2023
received:
12
04
2023
accepted:
30
05
2023
pubmed:
17
6
2023
medline:
17
6
2023
entrez:
17
6
2023
Statut:
aheadofprint
Résumé
Fine needle aspirations are infrequently performed on the spleen due to concerns for hemorrhagic complications. As a result, splenic lesions can be challenging to diagnose given the limited amount of available specimen. Metastasis to the spleen is rare and metastatic neuroendocrine tumors to the spleen are scarce in literature. The diagnosis of splenic lesions from fine needle aspirate entails processing which prolongs the turnaround time, particularly if the cytomorphology is non-typical and a limited sample can further complicate this process. We describe a case in which flow cytometry performed on fine needle aspiration of a splenic lesion suggested a diagnosis of neuroendocrine neoplasm involving the spleen. Further workup confirmed this diagnosis. Flow cytometry can recognize neuroendocrine tumors involving the spleen in a timely manner so that appropriate immunohistochemistry tests on limited specimens can be performed to aid in their accurate diagnosis.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
E259-E262Informations de copyright
© 2023 Wiley Periodicals LLC.
Références
Lam KY, Tang V. Metastatic tumors to the spleen: a 25-year clinicopathologic study. Arch Pathol Lab Med. 2000;124(4):526-530. doi:10.5858/2000-124-0526-MTTTS
Sakuma Y, Yasuda Y, Sata N, et al. Pancreatic neuroendocrine tumor with metastasis to the spleen: a case report. BMC Cancer. 2017;17(1):37. doi:10.1186/s12885-016-3020-8
Nasr S, Khsiba A, Mahmoudi M, Mohamed AB, Bouasida M, Hamzaoui L. Spleen metastases secondary to gastric neuroendocrine carcinoma: case report. Pan Afr Med J. 2022;42:131. doi:10.11604/pamj.2022.42.131.34091
“Turnaround Time (TAT)-Biopsies-Cap.” CMS Measure ID/CMS QCDR ID: CAP 22 Measure Title: Turnaround Time (TAT)-Biopsies, American Medical Association. 2020 https://documents.cap.org/documents/cap-22-turnaround-time-biopsies-2021.pdf
Farinola MA, Weir EG, Ali SZ. CD56 expression of neuroendocrine neoplasms on immunophenotyping by flow cytometry: a novel diagnostic approach to fine-needle aspiration biopsy. Cancer. 2003;99(4):240-246. doi:10.1002/cncr.11458
Bryson GJ, Lear D, Williamson R, Wong RC. Detection of the CD56+/CD45− immunophenotype by flow cytometry in neuroendocrine malignancies. J Clin Pathol. 2002;55(7):535-537. doi:10.1136/jcp.55.7.535
Sauer J, Sobolewski K, Dommisch K. Splenic metastases-not a frequent problem, but an underestimate location of metastases: epidemiology and course. J Cancer Res Clin Oncol. 2009;135(5):667-671. doi:10.1007/s00432-008-0502-3
Berge T. Splenic metastases. Frequencies and patterns. Acta Pathol Microbiol Scand A. 1974;82(4):499-506.
Pugalenthi A, Bradley C, Gonen M, et al. Splenectomy to treat splenic lesions: an analysis of 148 cases at a cancer center. J Surg Oncol. 2013;108(8):521-525. doi:10.1002/jso.23433
Gatenby PA, Mudan SS, Wotherspoon AC. Splenectomy for non-haematological metastatic malignant disease. Langenbeck's Arch Surg. 2011;396(5):625-638. doi:10.1007/s00423-011-0746-2
Patel N, Dawe G, Tung K. Ultrasound-guided percutaneous splenic biopsy using an 18-G core biopsy needle: our experience with 52 cases. Br J Radiol. 2015;88(1055):20150400. doi:10.1259/bjr.20150400
Jayasinha Y. Decreasing turnaround time and increasing patient satisfaction in a safety net hospital-based pediatrics clinic using lean six sigma methodologies. Qual Manag Health Care. 2016;25(1):38-43. doi:10.1097/QMH.0000000000000083
Wong-Arteta J, Rey M, Aragón L, Gil-Rodríguez E, Bujanda L. The utility of flow cytometry in the diagnostic work up of malignant effusions due to nonhematopoietic neoplasms. Cytometry B: Clin Cytom. 2020;98(6):504-515. doi:10.1002/cyto.b.21886